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in the mouse carcinoma after treatment with RT + CTLA-4 
blockade. Significant changes in TCR repertoire were also 
seen in peripheral blood of responding patients, supporting 
the hypothesis that RT can convert the irradiated tumor into 
an in situ vaccine.  
Immunogenic cell death is induced by radiation in a dose-
dependent way, with higher ablative single doses being more 
effective in vitro (Golden et al., OncoImmunology 2014). 
However, in vivo the interaction between the dying cancer 
cells and the pre-existing immune microenvironment 
determines the ability of RT to prime effective anti-tumor T 
cell responses. For instance, we have shown that the number 
of DCs available in the tumor and draining lymph nodes to 
uptake and present the antigens released by RT is a critical 
determinant of the magnitude of the immune response 
elicited (Pilones et al., J Immuntother Cancer 2014). We have 
recently found that canonical pathways mediating the 
induction of type I interferon responses in epithelial cells 
during viral infection are induced by fractionated but not 
single dose RT. RT-induced cancer cell intrinsic interferon-I 
production enhanced DCs infiltration and was required for 
development of tumor-specific T cells capable of rejecting 
not only the irradiated tumor but also non-irradiated 
metastases (abscopal effect). This explains, at least in part, 
the synergy of fractionated RT regimens (8GyX3 or 6GyX5), 
but not a single ablative RT dose of 20 Gy, with anti-CTLA-4 
in achieving abscopal responses against poorly immunogenic 
carcinomas (Dewan et al., Clin Cancer Res 2009). In addition, 
we have shown that immunosuppressive mediators such as 
TGF-beta, which is released in its active form by RT-
generated ROS, need to be neutralized to improve DC 
maturation and activation of T cells capable of rejecting the 
tumor (Vanpouille-Box et al., Cancer Res 2015).  
Overall, optimal RT regimens combined with targeting of 
dominant immune suppressive pathways enable RT use as a 
simple, widely available tool for patient and tumor-specific 
in situ vaccination.  
Supported by DOD BC100481P2, NIH R01CA201246, Breast 
Cancer Research Foundation, and The Chemotherapy 
Foundation.  
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Recent clinical trials revealed the impressive efficacy of 
immunological checkpoint blockade in different types of 
metastatic cancers. Such data underscore that 
immunotherapy is one of the most promising strategies for 
cancer treatment. In addition, preclinical studies provide 
evidence that chemotherapy and radiotherapy have the 
ability to stimulate the immune system, resulting in anti-
tumor immune responses that contribute to clinical efficacy 
of these agents. These observations raise the hypothesis that 
the next step for cancer treatment is the combination of 
cytotoxic agents and immunotherapies. This presentation will 
discuss the immune-mediated effects of anticancer agents 
and their clinical relevance, the biological features of 
immune checkpoint blockers and finally, the rationale for 
novel therapeutic strategies combining anticancer agents and 
immune checkpoint blockers. 
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The evolution of radiation oncology is based on the increasing 
integration of imaging data into the design of highly 
personalized cancer treatments.  
Technologically advanced image-guided delivery techniques 
have made modern radiotherapy treatment extremely 
flexible in term of optimal sparing of the organs at risk and 
shaping different prescribed target doses to tumor volumes 
delineated on the basis of functional imaging information.  
In the last 10 years a remarkable development of more 
sensitive and specific signals (quantitative dynamic contrast-
enhanced CT and MRI; diffusion MRI, specific PET tracers, 
multi-parametric MRI/PET, etc) have contributed to the 
prescription and design of radiation treatment plan.  
The main contribution of new imaging modalities can be 
summarized:  
- Improved delineation of target and normal structures (new 
hybrid imaging devices offer co-registration of anatomical, 
functional and molecular information); a further refinement 
of this approach is the possibility to shape the dose gradually 
according to the functional parameters (dose painting);  
- Adaptation, the radiation technique defined at planning 
simulation can often require modification not only due to the 
changes in patient anatomy but because of early variations of 
certain imaging related parameters surrogates of treatment 
outcome.  
- Predictive biomarkers, the use of more advanced image 
analysis methods (texture feature parameters) could be a 
surrogate of important tumor characteristics and have a 
higher predictive and prognostic power than simpler numeric 
approaches;  
- Radiomics, the extraction of large amount from diagnostic 
medical images may be used to underlying molecular and 
genetic characteristics and this genetic profile may change 
over time because of therapy.  
Despite the multiple benefits that the quantitative imaging 
can offer for radiation therapy improvement, there are a 
number of technical challenges and organisational issues that 
need to be solved before its fruitful integration into RT 
treatment planning process.  
The main aspects covered by this lecture will be:  
- Standardized procedures for acquisition, reconstruction and 
elaboration of PET data set;  
- Methods for delineation of the PET-related biological target 
volume (BTV). 
- Data acquisition and processing techniques used to manage 
respiratory motion in PET/CT studies; the use of personalized 
motion information for target volume definition. 
- A procedure to improve target volume definition when using 
contrast enhanced 4D-CT imaging in pancreatic carcinoma.  
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Pubmed references, presentations and posters during a lot of 
Conferences (ESTRO, EFOMP, ESMRMB, EANM,...) are 
introducing a lot of biological and functional imaging for 
radiotherapy applications: MRI, PET, SPECT, functional CT 
are able to support radiation therapy for target and Organ of 
Risk definition. Looking at the EUROPEAN GUIDELINES ON 
MEDICAL PHYSICS EXPERT (RP 174) the competence on 
biological and functional imaging is not specific item into RT 
skill and competences. We can find the key activities of MPEs 
inside the following: Diag.& Therap. NM Internal Dosimetry 
Measurements( K23: Explain methods for determining 
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patient-specific organ masses including the respective errors 
and explain the difference between morphological and 
functional volume of organs), Scientific Problem Solving 
Service (K36: Explain the physics principles underpinning MR 
angiography (MRA) and flow, perfusion and diffusion imaging, 
functional MR imaging (fMRI) and BOLD contrast, MR 
spectroscopy (MRS), parallel imaging, DCE-MRI) and Clinical 
Involvement in D&IR (K88: Explain the use of the various 
modalities for anatomical and functional imaging and K90: 
Interpret anatomical and functional 2D/3D images from the 
various modalities and recognize specific anatomical, 
functional and pathological features). The curricula defines 
the SKC not specificying how MPE is involved in RT because 
the functional imaging (in general) and in radiotherapy (in 
particular), needs a strong interdisciplinary team: MPE expert 
in radiation oncology and MPE expert in functional imaging 
should approach the problem together with clinical support. 
The University and Accreditation training in Europe is not the 
same and each country differs: in many of them, MPE 
accreditation in Radiotherapy does not require the 
accreditation in Diagnostic Imaging. In the next future, 
requirements of physics application in radiotherapy willneed 
to include the expertise in diagnostic imaging with particular 
attention to functional imaging, but the interdisciplinary 
approach is more effective in the clinical practice. EFOMP 
and ESTRO working Group is working to define the potential 
topics for MPE education and training e-learning platform; 
the knowledge and the expertise in this field will be more 
and more important. 
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From the earliest times mankind has struggled to improve his 
productive means; skills, tools and machines. Aristotle 
dreamed of the day when “every tool, when summoned, or 
even of its own accord, could do the work that befits it”. 
However, we have to wait till 1956 to see the name 
“automation” appearing in dictionaries. Automation was 
defined as: “the use of various control systems for operating 
equipment such as machinery, processes in factories, aircraft 
and other applications with minimal or reduced human 
intervention”. In the fifties it was heralded as the threshold 
to a new utopia, in with robots and “giant brains” would do 
all work while human drones reclined in a pneumatic bliss. 
The pessimists pictured automation as an agent of doom 
leaving mass unemployment and degradation of the human 
spirit in its wake. Sixty years from those first papers and 
books in automation we can see that neither the optimistic 
perspectives nor the most catastrophic views have come 
true; we still have to wake up to go to work each morning 
and job have changed but not disappeared. The use of 
automation in different fields is not homogeneous. For 
instance, planes, trains and ships are already heavily 
automated while in our field, radiation oncology and 
medicine in general, automation has not been fully 
exploited. Repetitive tasks can be easily automated and this 
will on one side avoid tedious thinking that must be done 
without error and on the other side will free time to more 
creative thinking which will satisfy and give us more joy. 
Treatment planning, evaluation of treatment planning and QA 
at treatment unit are areas that are being explored by 
different research groups. We can automate tasks but 
automations means much more than this. Automation is a 
means of analysing, organising and controlling our processes. 
But how far can we go? Can we design a system able to take 
complex decisions and not only binary ones such as pass/fail 
for a quality control test? Yes we can, if we exploit machine 
learning algorithms. Machine learning will be able to predict 
the best possible solution for a particular problem and will 
form the core of both quality control methods (comparing the 
predictions with the actual results). One of the side products 
of automation is standardisation of practice. Let’s take 
treatment planning as an example. Treatment planning is a 
time consuming task and the resulting plans depend largely 
on the ability of the planer. Automation in treatment 
planning has shown to reduce the time needed to achieve 
plans with less variability and quality. The fact that most 
vendors offer the possibility of writing scripts to automate 
checks and to query treatment machine log-files and 
treatment planning systems data is welcomed and will 
facilitate the clinical implementation of automation. For 
management, automation poses the problem of adapting to 
new concepts and new methods of working and the processes 
have to be adjusted. Risk analysis has to be re-evaluated and 
probably different risk mitigation strategies will have to be 
implemented. For the worker, automation involves changes 
in the way of working. In particular, clinical medical 
physicists will have to design performance tests to evaluate 
these automated systems. To face the challenges that 
automation brings to our field, medical physics curricula 
should include IT and also programming. With automation 
comes a choice between additional leisure and additional 
products. I would strongly advocate for more time for 
scientific creative thinking which is needed to contribute to 
significant advances in medicine and in particular the cure of 
cancer. 
 
SP-0597  
Automated QA for radiotherapy treatment planning 
S. Petit
1Erasmus MC Cancer Institute, Department of Radiation 
Oncology, Rotterdam, The Netherlands 
1,2, Y. Wang1, B. Heijmen1 
2Massachusetts General Hospital - Harvard Medical School, 
Department of Radiation Oncology, Boston MA, USA 
 
The need of QA for individual treatment plans 
The achievable degree of organ sparing with radiation 
treatment planning is highly dependent on the patient 
anatomy. Radiation treatment planning with a commercial 
TPS is an iterative trial and error process. Even for 
experienced dosimetrists or physicians it is very difficult to 
judge whether the dose to OARs cannot be lowered further. 
As a result, the quality of a treatment plan is highly 
dependent on the available planning time, the experience 
and talent of the treatment planner and how critically the 
treatment plan is being reviewed. In a recent study by our 
group it was shown that after trying to further improve 
already approved IMRT treatment plans for prostate cancer 
patients, the rectum dose could be further reduced by on 
average 6 Gy (range 1-13 Gy), without negative consequences 
for PTV or other OARs [1]. In conclusion, there is a clear need 
for treatment planning quality assurance (QA) protocols to 
guarantee that for each patient the generated plan is indeed 
optimal for the patient-specific anatomy.  
 
Different strategies for treatment planning QA 
In recent years different groups have proposed different 
strategies for treatment planning QA. The general idea is to 
predict the lowest achievable dose for OARs and compare the 
achieved dose of the treatment plan with the predictions. As 
long as differences between the predictions and the achieved 
doses to the OARs exceed some predefined action levels, 
treatment planning should continue, to try to further lower 
the doses. Most methods rely on a database with plans of 
prior patients treated for the same tumor site. Because the 
achievable degree of OAR sparing is highly dependent on 
patient anatomy only treatment plans of prior patients with 
anatomies similar as the new patient are selected. Next 
these prior plans are used to predict achievable DVH metrics 
for the new patient. The main distinctions between the 
different methods are (i) the manner in which similarity in 
anatomy is assessed and (ii) how the dose distributions of the 
similar prior patients are used to predict DVH parameters for 
new patients. 
Similarity in anatomy can be assessed using distinctive 
anatomical features. These can vary from very simple such as 
the percentage overlap of the PTV with an OAR[2]; to an 
intermediate level of complexity such as the Overlap Volume 
